Two long term extension studies of tofacitinib, (a JAK1/JAK3 inhibitor with a nearly identical target profile to that of oclacitinib), in patients with rheumatoid arthritis found that fewer than 5% experienced neutropenia of any degree, and most were mild in severity [29]. Here, JAK3 is linked to neutropenia.